Policy / Regulatory

NMPA Expands Generic Drug Catalog with 74th and 75th Batches for Quality Consistency Evaluation

CompanyDrug

China Grand Pharmaceutical Gets NMPA Green Light for mRNA Cancer Vaccine ARC01 Phase I Study

CompanyDeals

China Anti-Cancer Association Forms Consortium for Standardizing Cancer Research Ethics Reviews

CompanyDrug

Boan Biotech Secures FDA Orphan Drug Designations for Two Claudin18.2 Targeting Candidates

CompanyDeals

Alphamab and 3D Medicines License Envafolimab Rights to Glenmark for Multiple Regions

CompanyDrug

Lingyi Biotechnology’s Gene Therapy Candidate LY-M001 Gets FDA Green Light for Gaucher’s Disease

CompanyR&D

WuXi Biologics Launches WuXiaADCC PLUS Platform for Non-Fucosylated Antibody Development

CompanyDrug

Phanes Therapeutics’ First-in-Class BsAb PT217 Accepted for Review by China’s CDE

CompanyDrug

Zhaoke Ophthalmology Secures NMPA Approval for Presbyopia Treatments Brimochol PF and CarbacholPF

Company

Harbour BioMed Gets FDA Green Light for Phase I Study of BsAb Targeting PD-L1 and CD40

Company

Abbott Reports Mixed 2023 Results with Q4 Growth Offsetting Full-Year Decline

CompanyDeals

Sanofi Acquires Rare Disease Candidate INBRX-101 in $1.7 Billion Deal